Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma (MCL). 

CAR T-cell therapy is a new ​therapeutic modality in MCL, so additional research is needed, says Wang.

In the phase 2 ZUMA-2 trial, it was discovered that certain cytokines are associated with efficacy and toxicity​, explains Wang. Moreover, future research efforts should aim to develop new measures that could enhance efficacy and minimize​ toxicity in these patients. 

As the ZUMA-2 trial was relatively small, larger studies are necessary to obtain further insight on​ the utility of minimal residual disease, as well as cytokine ​profiling, Wang concludes.